SCHEMBL7149883

SCHEMBL7149883

Cc1ccc2sc(SCCCS(=O)(=O)Nc3ccccc3C)nc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 9/20 0.53
ALDH1A1 P00352 6/20 0.53
MAPT P10636 5/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
SMN1; SMN2 Q16637 7/20 0.45
HSD17B10 Q99714 1/20 0.45
HTT P42858 4/20 0.42
POLB P06746 2/20 0.42
KMT2A Q03164 1/20 0.42
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.40
GFER P55789 1/20 0.40
NPC1 O15118 1/20 0.40
RECQL P46063 1/20 0.40
RAB9A P51151 1/20 0.40
ALOX5 P09917 2/20 0.40
PKM P14618 1/20 0.40
CYP1A2 P05177 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7153854 0.97 LMNA (0.52) LMNAALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL7144723 0.94 LMNA (0.49) LMNAALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL7151670 0.89 LMNA (0.65) LMNAALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL7153019 0.88 MAPT (0.43) LMNAALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL7144783 0.87 LMNA (0.46) LMNAALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL7148438 0.86 LMNA (0.64) LMNAALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL7146609 0.85 MAPT (0.42) LMNAALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL7153246 0.85 ALDH1A1 (0.43) LMNAALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL7146167 0.84 ALDH1A1 (0.43) LMNAALDH1A1MAPTL3MBTL1SMN1; SMN2
SCHEMBL7153029 0.84 ALDH1A1 (0.46) LMNAALDH1A1MAPTL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6642263-B2 Antitumor agents, sulfided benzothiazole derivative containing sulfonamide ICONIX PHARMACEUTICALS INC. 2003-11-04 US disclosed
US-20030176474-A1 Modulators of Rho C activity ICONIX BIOSCIENCES, INC. 2003-09-18 US disclosed
WO-2003043577-A2 MODULATORS OF RHO C ACTIVITY ICONIX PHARMACEUTICALS, INC. (US) 2003-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176474-A1 Modulators of Rho C activity RHOC, ARHGDIA, ROCK1 LMNA 1481/4885ALDH1A1 2919/4885MAPT 3839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.